UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $697.10 Million Holdings in McKesson Corporation $MCK

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of McKesson Corporation (NYSE:MCK) by 3.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 922,573 shares of the company’s stock after purchasing an additional 29,747 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.79% of McKesson worth $697,096,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. New Mexico Educational Retirement Board lifted its position in shares of McKesson by 7.1% during the second quarter. New Mexico Educational Retirement Board now owns 6,052 shares of the company’s stock worth $4,573,000 after purchasing an additional 400 shares in the last quarter. Royal London Asset Management Ltd. increased its position in McKesson by 1.1% in the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock worth $84,809,000 after purchasing an additional 1,216 shares during the period. Toth Financial Advisory Corp raised its holdings in McKesson by 2.6% during the 2nd quarter. Toth Financial Advisory Corp now owns 16,247 shares of the company’s stock worth $12,276,000 after purchasing an additional 410 shares during the last quarter. Mufg Securities Americas Inc. raised its holdings in McKesson by 6.8% during the 2nd quarter. Mufg Securities Americas Inc. now owns 3,621 shares of the company’s stock worth $2,736,000 after purchasing an additional 232 shares during the last quarter. Finally, Ferguson Wellman Capital Management Inc. lifted its position in McKesson by 3.4% during the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 28,236 shares of the company’s stock valued at $21,335,000 after purchasing an additional 935 shares during the period. 85.07% of the stock is owned by institutional investors.

Insider Transactions at McKesson

In other McKesson news, Director Bradley E. Lerman sold 301 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Thomas L. Rodgers sold 699 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total transaction of $513,953.73. Following the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,667,592.36. This represents a 23.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 23,111 shares of company stock valued at $18,011,274 over the last three months. 0.06% of the stock is currently owned by corporate insiders.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Expansion into precision medicine: McKesson agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion. Precision Medicine provides clinical research, laboratory testing and commercialization services for biotechnology and pharmaceutical companies, giving McKesson greater exposure to oncology, personalized medicine and specialty care. McKesson Doubles Down on Healthcare Growth With Precision Medicine Acquisition
• Positive Sentiment: Higher-growth service mix: The acquisition is expected to strengthen McKesson’s clinical research and commercialization capabilities and deepen relationships with biopharmaceutical companies and oncology practices. Investors may view the transaction as a way to reduce reliance on lower-margin pharmaceutical distribution and participate in growth tied to new drug development. What Does McKesson Gain From Its Push Into Oncology And Clinical Research?
• Neutral Sentiment: Portfolio repositioning amid workforce changes: Coverage noted layoffs at Rx Savings while McKesson plans the Precision Medicine acquisition. The combination highlights an ongoing reallocation of resources, although the near-term effect on earnings and integration costs remains uncertain. Amid Layoffs, McKesson Plans Acquisition
• Negative Sentiment: Cybersecurity incident disclosed: McKesson reported discovering a cybersecurity incident on August 25 after the ShinyHunters group claimed it had stolen patient data. The company’s investigation and any resulting regulatory, remediation, privacy or reputational costs could weigh on sentiment, although the ultimate scope and financial impact were not yet clear. McKesson Discloses Breach After ShinyHunters Claims Patient Data Theft

Analysts Set New Price Targets

MCK has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $875.00 target price on shares of McKesson in a report on Friday, May 8th. UBS Group raised their price target on McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings downgraded McKesson from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, July 7th. Wells Fargo & Company boosted their target price on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Finally, Citigroup lifted their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $973.44.

McKesson Stock Performance

Shares of MCK opened at $895.59 on Friday. The firm has a market cap of $104.42 billion, a P/E ratio of 23.97, a PEG ratio of 1.76 and a beta of 0.30. McKesson Corporation has a twelve month low of $679.65 and a twelve month high of $999.00. The firm’s 50 day moving average price is $833.31 and its two-hundred day moving average price is $844.13.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company had revenue of $105.38 billion during the quarter, compared to the consensus estimate of $103.88 billion. During the same quarter in the prior year, the firm earned $8.26 earnings per share. The firm’s revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 44.65 earnings per share for the current fiscal year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is a positive change from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date is Tuesday, September 1st. McKesson’s dividend payout ratio is presently 10.06%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.